November 2023 in “Journal of Skin and Sexually Transmitted Diseases” Gefitinib can cause scalp skin issues and permanent hair loss.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
9 citations
,
February 2019 in “BMC cancer” M30 is a promising treatment for preventing hair loss during chemotherapy.
April 2023 in “Journal of Investigative Dermatology” Aminoacridine and Abemaciclib, especially combined with Minoxidil, show promise for treating hair loss.
February 2026 in “MedBA Medicine” Erlotinib can cause unexpected side effects like eyelash growth and scarring.
April 2016 in “Journal of Investigative Dermatology” Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.
August 2018 in “SDÜ SAĞLIK BİLİMLERİ DERGİSİ” No method fully prevents hair loss from chemotherapy, but some methods can reduce it and improve quality of life.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
January 2019 in “대한피부과학회지” Metformin promotes hair growth by affecting cell growth and protein signaling related to hair growth.
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” January 2023 in “Cutaneous and Ocular Toxicology”
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
September 2023 in “Journal of the American Academy of Dermatology” BAP1 mutations are rare in pediatric melanocytic tumors and may develop later in life.
February 2026 in “Dermatology and Therapy” Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
32 citations
,
August 1996 in “Journal of Investigative Dermatology” November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
August 2011 in “Reactions Weekly” A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.
November 2023 in “SKIN The Journal of Cutaneous Medicine”
58 citations
,
March 2020 in “Scientific Reports” EGFR-TKIs can cause significant skin, nail, and organ side effects.
March 2022 in “International Journal of Trichology” Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.